Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

argenx

Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to develop the med across various blood cancers and disorders in December 2018.

Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab

Apple

Salesforce

Cisco Systems

Home Depot

Intel

Coca-Cola

Lizhi

Microsoft

NIKE

Newpark Resources

Travelers

UnitedHealth Group

Walgreens

Two new sample breakout stocks for Week 23 with better than 10% short-term upside potential. This past week, the peak gains were in RMO +17.4% and NNDM +10.8% with all 4 picks gaining more than +5% in less than 5 days.

Week 23 MDA Breakout Stocks - June 2021: Short-Term Picks To Give You An Edge

Stryker

Zimmer Biomet Hlds

As hospitals address the major backlog of pandemic-postponed elective surgeries, medical device makers -- and their stock prices -- could benefit.

This Part of the Reopening Trade Is Just Getting Started

Johnson & Johnson (JNJ) CEO Alex Gorsky Presents at Bernstein's 37th Annual Strategic Decisions Virtual Conference (Transcript)

Johnson & Johnson's litigation risks are weighing on its credit profile, according to Moody's Investors Service, citing the news this week that the Supreme Court denied the company's appeal regarding a talc lawsuit and ordered it to pay $2.5 billion to 20 plaintiffs. The payment includes the original $2.1 settlement, plus interest.

Moody's: J&J faces 'litigation exposure' from talc lawsuits, proposed opioid settlement

Shares of Johnson & Johnson rose 0.4% in morning trading, in the wake of the U.S. Supreme Court's denial of the request to review a Missouri court verdict regarding various talc cases against the consumer products and drug maker. As a result of the Supreme Court decision, J&J disclosed in an 8-K filing with the Securities and Exchange Commission late Tuesday that it will make a $2.5 billion payment, including interest, in June.

J&J stock gains after Moody's says $2.5 billion payment for talc claims doesn't affect Aaa rating

The U.S. Supreme Court rejects J&J's (JNJ) appeal against a lower court verdict of $2.1 billion in damages in a litigation related to its talc-based baby powder.

J&J (JNJ) to Pay $2.5B in Baby Powder Case on Appeal Rejection

AstraZeneca

BioNTech SE

Dyadic International Inc., DE

The party is apparently “On” as far as the developed world's sense of “reopening” is concerned. But the global truth is far removed from this celebration, as less than 20% of the world's population have had access to a vaccine.

The Vaccine Investment Hypothesis, and What's Next (AZN, JNJ, DYAI, BNTX)

Apellis Pharma

BridgeBio Pharma Inc

Lantheus Holdings

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

The company has set aside nearly $4 billion as a "litigation expense."

Supreme Court Rules Johnson & Johnson Must Pay $2.1 Billion in Baby Powder Lawsuit

Johnson & Johnson (NYSE: JNJ) will not be getting out of its obligation to pay up for losing a civil court case over its baby powder products that allegedly contained asbestos. On Tuesday, the U.S. Supreme Court announced it would not hear the company's appeal of a $2.1 billion verdict from a 2018 trial in Missouri involving women who argued that the products contributed to their ovarian cancer.

Supreme Court Denies Johnson & Johnson's Challenge to Baby Powder Cancer Judgement

The lawsuit is one of many filed on behalf of thousands of women who claim J&J's talc-based products like baby powder contributed to their ovarian cancer.

Supreme Court rejects J&J's appeal of $2B talcum powder cancer verdict

The Supreme Court rejected Johnson & Johnson's appeal of a $2.1 billion penalty over allegations that its talc powder caused ovarian cancer.

Supreme Court rejects Johnson & Johnson's appeal of $2 billion penalty in baby powder cancer case

Supreme Court rejects Johnson & Johnson's appeal of $2 billion talc verdict

The company challenged a ruling in favor of women who alleged the company's products caused ovarian cancer.

Supreme Court Won't Hear Johnson & Johnson Challenge Of $2 Billion Baby Powder Lawsuit

The U.S. Supreme Court on Monday declined to hear Johnson & Johnson's bid to overturn a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in the company's baby powder and other talc products.

U.S. Supreme Court rebuffs J&J appeal over $2 billion baby powder judgment

The US Supreme Court has declined to hear Johnson & Johnson's appeal against a $2.12bn (£1.5bn) damages award to women who say they developed ovarian cancer from using the company's talc products.

US Supreme Court rejects Johnson & Johnson appeal of $2bn talc verdict

The talcum powder cancer case features former independent counsel Kenneth Starr, who is representing the women who sued Johnson & Johnson for $2 billion.

Johnson & Johnson asks Supreme Court to void $2B talcum powder cancer verdict

Amazon

These companies are strong choices to hold onto for a long time.

2 Stocks for Beginning Investors

Himax Tech

Nano Dimension

Two new sample breakout stocks for Week 22 with better than 10% short-term upside potential. This past week the portfolio gained +4.4% led by gains in CDEV +15.6% and 3 out of 4 picks gaining more than +6.2% in less than 5 days.

Week 22 MDA Breakout Stocks - June 2021: Short-Term Picks To Give You An Edge

Mastercard

NextEra Energy

Waste Connections

The growth catalysts for these stocks are so compelling, you'd want to own them forever.

5 Stocks You Can Buy and Hold Forever

Pfizer

The combination of stability and innovation makes these giants safe bets for long-term returns.

2 Healthcare Stocks That Could Be Millionaire-Makers

Dollar General

Adaptimmune Therapeutics

Guess?

Teladoc

With the trading day more than halfway over, the markets were moving higher going into the weekend.

Dollar General, HP, Johnson & Johnson and More Friday Afternoon Analyst Calls

Emergent BioSolutions

The FDA and Johnson & Johnson (NYSE: JNJ) are expected to announce that contamination problems at Emergent BioSolutions Inc's (NYSE: EBS) Baltimore Bayview plant have been resolved, and production is set to resume, the Wall Street Journal reported. The deal with the FDA could free up already manufactured doses of the vaccine that have been in quarantine and allow for the production of new doses.

News for Johnson & Johnson Stock (JNJ)